Orlistat

Orlistat is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m², or overweight patients (BMI ≥ 28 kg/m²) with associated risk factors.

Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.

alli is indicated for weight loss in adults who are overweight (body mass index, BMI, ≥28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.

Use for weight loss in overweight adults, 18 years and older, when used along with a reduced-calorie and low-fat diet

XENICAL (orlistat), when used in conjunction with a mildly hypocaloric diet, is indicated for: • obesity management including weight loss and weight maintenance; • reducing the risk of weight regain in obese patients after prior weight loss.

g. hypertension, type 2 diabetes, dyslipidemia, excess visceral fat). The weight loss induced by the combination of XENICAL and a mildly hypocaloric diet results in an improvement of risk factors and comorbidities including hypercholesterolemia, impaired glucose tolerance, hyperinsulinemia, hypertension, reduction of visceral fat and waist circumference.

The weight loss induced by XENICAL improves glycemic control in diabetic patients and reduces the risk of developing type 2 diabetes in obese patients (BMI* ≥ 30 kg/m2) with impaired glucose tolerance. The effect of XENICAL on weight loss is adjunctive to that of diet and exercise.

XENICAL can be used in combination with anti-diabetic agents (sulfonylureas, metformin, insulin) to improve blood glucose control in overweight or obese type 2 diabetes patients who are inadequately controlled on diet, exercise, and one or more of a sulfonylurea, metformin, or insulin.